Risk of second breast cancer according to estrogen receptor status and family history
- 277 Downloads
A recent study reported an increased risk of contralateral estrogen-negative breast cancer after a first primary estrogen-negative breast cancer. Our study aims to confirm this result and to evaluate how the risk of second breast cancer occurrence is affected by family history of breast cancer and anti-estrogen treatment. We included all 4,152 women diagnosed with breast cancer between 1995 and 2007, using data from the population-based Geneva Cancer Registry. We compared the incidence of second breast cancer among patients according to estrogen receptor (ER) status with that expected in the general population by age-period Standardized Incidence Ratios (SIRs). Among the cohort, 63 women developed second breast cancer. Patients with ER-positive first tumors had a decreased risk of second breast cancer occurrence (SIR: 0.67, 95% CI: 0.48–0.90), whereas patients with ER-negative primary tumors had an increased risk (SIR: 1.98, 95% CI: 1.19–3.09) limited to ER-negative second tumors (SIR: 7.94, 95% CI: 3.81–14.60). Patients with positive family history had a tenfold (SIR: 9.74, 95% CI: 3.57–21.12) higher risk of ER-negative second tumor which increased to nearly 50-fold (SIR: 46.18, 95% CI: 12.58–118.22) when the first tumor was ER-negative. Treatment with anti-estrogen decreased the risk of second ER-positive tumors but not ER-negative tumors. The risk of second ER-negative breast cancer is very high after a first ER-negative tumor, in particular among women with strong family history. Surveillance and prevention of second cancer occurrence should consider both ER status of the first tumor and family history.
KeywordsBreast cancer Estrogen receptor status Second cancer Family history
We thank Stina Blagojevic for technical and editorial assistance, the Cancer registry team for providing data and support, and Robin Schaffar for assistance in statistical analyses.
The set-up of the Family breast cancer registry was financially supported by the Swiss Cancer League (OCS 01380-08-2003, OCS 02070-04-2007); HM Verkooijen was financially supported by the Swiss Science Foundation, PROSPER Grant (3233-069350).
- 2.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials (1998) Lancet 351 (9114): 1451–1467Google Scholar
- 11.Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, Isaacs C, Kim-Sing C, Moller P, Neuhausen SL, Metcalfe K, Sun P, Narod SA (2005) A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev 14(6):1534–1538PubMedCrossRefGoogle Scholar
- 19.Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, Huff MO, McGregor WG, Klinge CM (2006) Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer 13(1):113–134PubMedCrossRefGoogle Scholar
- 25.Bouchardy C (2007) Switzerland, Geneva. In: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (eds) Cancer incidence in five continents vol. IX. International Agency for Research on Cancer, Lyon, pp 369–370Google Scholar
- 26.Fritz A, Percy C, A A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S (eds) (2000) ICD-O International classification of diseases for oncology. World Health Organization, GenevaGoogle Scholar
- 27.Coleman MP, Hermon C, Douglas A (1989) Person-Years (PYRS). A Fortran program for cohort study analysis. IARC Internal Report no. 89/006. International Agency for Research on Cancer, LyonGoogle Scholar
- 29.Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechthold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27(35):5887–5892PubMedCrossRefGoogle Scholar
- 31.Porter PL, El Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91(23):2020–2028PubMedCrossRefGoogle Scholar
- 34.Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6(7):1076–1087PubMedGoogle Scholar